Novo Nordisk opens first Pharmatech branch office in Singapore
pharmafile | October 22, 2019 | News story | Manufacturing and Production | Novo Nordisk, Singapore, pharma
Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening event attended by stakeholders, staff and the company’s customers.
The new site, located in the East building of the 37-storey, 150 metre skyscraper complex known as The Gateway at 152 Beach Road, is the first branch office Novo Nordisk Pharmatech, a subsidiary of its global parent focused on the supply of pharmaceutical and biopharmaceutical ingredients, including recombinant insulin and quaternary ammonium compounds.
Rasmus Hother le Fevre, Managing Director and Corporate Vice President of Novo Nordisk Pharmatech A/S, was present at the event on 15 October, where he commented:
“We are thrilled to be expanding our footprint into Asia. This new office will serve as a hub to expand our business in Asia and it is in close proximity to some of the world’s leading biopharmaceutical companies. The location will give us access to a very large pool of the biopharmaceutical development in the region which is a key focus of the company.
“Our new Singapore location extends Novo Nordisk Pharmatech’s heritage of delivering high quality quaternary ammonium compounds as well as recombinant insulin for cell culture media to the pharmaceutical and biopharmaceutical industry.”
He continued: “A local Singapore branch office was a logical step in our business growth strategy and presents a unique opportunity for Novo Nordisk Pharmatech to strengthen our presence. We have been active in this thriving market for several years. The local office in Singapore will allow us to serve both local companies in Singapore as well the rest of the Asian markets much more efficiently.”
Matt Fellows
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
